TELO News and Press, Telomir Pharmaceuticals Inc. From 11/11/25

Ensysce Biosciences Inc. (ENSC) is expected to report $-0.85 for Q3 2025 IO Biotech Inc. (IOBT) is expected to report $-0.31 for Q3 2025 Lifeward Ltd. (LFWD) is expected to report $-0.14 for Q3 2025 Life360 Inc. (LIF) is expected to report $0.03 for Q3 2025 Pixelworks Inc. (PXLW) ...

New findings highlight Telomir-1's impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ACCESS Newswire / October 23, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" o...

2025-10-21 08:10:55 ET More on Telomir Pharmaceuticals, Inc. Seeking Alpha’s Quant Rating on Telomir Pharmaceuticals, Inc. Historical earnings data for Telomir Pharmaceuticals, Inc. Financial information for Telomir Pharmaceuticals, Inc. Read the ful...

Unifying global IP rights and enabling up to $5 million in potential shareholder contributions, the agreement strengthens Telomir's foundation for partnerships, licensing, and long-term value creation. MIAMI, FLORIDA / ACCESS Newswire / October 21, 2025 / Telomir Pharmaceuticals, Inc. (...

Findings complement previously announced results in triple-negative breast cancer (TNBC) and prostate cancer models, highlighting Telomir-1's consistent impact on cancer cell survival pathways. MIAMI, FLORIDA / ACCESS Newswire / October 14, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TE...

2025-10-09 09:30:23 ET Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) , a preclinical-stage biotechnology company focused on developing therapies for cancer, aging, and age-related diseases, has announced groundbreaking findings regarding its lead candidate, Telomir-1. The new researc...

New findings show Telomir-1 shuts down cellular energy pathways and mitochondrial function in aggressive breast cancer cells, leading to cell death through iron-dependent regulation. MIAMI, FL, 2654 / ACCESS Newswire / October 9, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telo...

2025-10-07 15:12:31 ET DENVER, Colo., Oct 07, 2025 ( 247marketnews.com )- With just one hour left in the trading day, momentum is building behind a wave of innovation-centric small and mid-cap names, as investors are rotating into high-conviction growth stories heading into the close. ...

Findings show that Telomir-1 restores the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of MASPIN and RASSF1A - genes that help block invasion, limit metastasis, and improve chemotherapy responsiveness in aggressive prostate cancer models. MIAMI, FLORIDA / A...

New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially representing a novel frontier in epigenetic therapy where no existing candidates have shown comparable breadth. MIAMI, FLORIDA / ACCESS Newswire / ...